HSC Exam Practice

Sample response. Insulin resistance is the state in which body cells such as muscle, liver and fat respond poorly to insulin, so a normal insulin concentration no longer produces normal glucose uptake. In early Type 2 diabetes the pancreatic beta cells compensate by working harder and secreting more insulin, which keeps blood glucose near normal for a period.

Marking notes. 1 mark for defining insulin resistance as reduced cellular response to insulin. 1 mark for identifying increased insulin secretion by beta cells as the compensatory response. Do not award the second mark for "the pancreas stops working", which describes the later stage.

Sample response. A treatment is an intervention that acts on the disease mechanism or its symptoms. Metformin is a treatment because it reduces glucose released by the liver and improves how tissues respond to insulin, so it directly lowers blood glucose. Monitoring is the collection of evidence about whether the plan is working. HbA1c is monitoring because it estimates average blood glucose over the previous two to three months; it does not change glucose itself, but the trend is used to decide whether to continue, adjust or escalate treatment.

Marking notes. 1 mark for defining treatment as acting on mechanism or symptoms, with metformin correctly described. 1 mark for defining monitoring as evidence gathering, with HbA1c correctly described as an average over about two to three months. 1 mark for the explicit statement that HbA1c does not itself lower glucose but informs a decision.

Sample response. Metformin reduces the amount of glucose the liver releases into the blood, so less glucose enters the circulation. It also improves the sensitivity of muscle and fat tissue to insulin, so those tissues take up glucose more effectively at a given insulin concentration. Because it works this way it lowers blood glucose without forcing already-strained beta cells to secrete still more insulin.

Marking notes. 1 mark for reduced hepatic glucose output. 1 mark for improved insulin sensitivity in peripheral tissue. 1 mark for recognising that it does not stimulate further insulin secretion, or for otherwise linking both actions to a fall in blood glucose.

Sample response. Two complications are cardiovascular disease and kidney disease. Accept also retinal damage or peripheral nerve damage. The common mechanism is that persistently high blood glucose progressively damages blood vessels, particularly the small vessels supplying the kidney, retina and nerves, and accelerates damage in larger arteries. Because the damage accumulates with the duration and degree of hyperglycaemia, management aims to lower glucose and to monitor blood pressure, lipids and kidney function so complication risk is reduced rather than only symptoms treated.

Marking notes. 1 mark per correctly named complication (maximum 2). 1 mark for identifying progressive damage to blood vessels and nerves caused by chronic hyperglycaemia as the shared mechanism.

Sample response. Remission means blood glucose has returned to the non-diabetic range without medication, which happens because losing visceral fat reduces the inflammatory signalling that disrupted insulin receptor function, so insulin sensitivity improves and overworked beta cells recover. However, the genetic predisposition to the disease is unchanged, and if weight is regained insulin resistance returns and blood glucose rises again. A cure would mean the disease could not return, so remission is a state that must continue to be maintained and monitored.

Marking notes. 1 mark for correctly defining remission as non-diabetic glucose without medication. 1 mark for the mechanism, reduced visceral fat improving insulin sensitivity and relieving beta cells. 1 mark for the reason it is not a cure, the predisposition remains and weight regain brings recurrence.

Sample response. In Type 2 diabetes the primary problem is not a shortage of insulin but that cells respond poorly to the insulin already present. Early in the disease the pancreas often secretes more insulin than normal, yet glucose remains high because the receiving tissues are resistant. Adding more insulin therefore treats the symptom rather than the mechanism, and it drives the beta cells harder at a time when they are already compensating and heading toward exhaustion. The logical first step is instead to make cells respond better to insulin, through activity, nutrition and weight management, and to reduce the glucose the liver releases using metformin. Insulin is added later, as escalation, if targets are not met or beta-cell function has declined so far that endogenous insulin is genuinely insufficient.

Marking notes. 1 mark for identifying that insulin is present, often in excess, and that the defect is cellular response. 1 mark for explaining that more insulin addresses the symptom not the mechanism. 1 mark for identifying the correct first-line approach, improving insulin sensitivity and reducing hepatic glucose output. 1 mark for recognising that insulin remains a legitimate escalation option once beta-cell function declines. This final mark distinguishes a complete answer from one that wrongly implies insulin is never used in Type 2 diabetes.

Sample response. Both groups begin at a mean HbA1c of about 8.9%. Group 1 falls to about 7.6% by month 12 but never reaches the 7.0% target, and then drifts upward to about 7.9% by month 24. Group 2 falls further and faster, reaching about 6.9% by month 12, below target, and holds at approximately 7.0% through to month 24. Group 2 is therefore both more effective and more durable.

The biological reason is that the two plans act on different numbers of points in the mechanism. Both groups receive metformin, which reduces hepatic glucose output and improves tissue insulin sensitivity. Group 2 additionally receives a structured lifestyle program, which acts on insulin resistance itself by increasing physical activity and reducing excess visceral fat, so insulin receptor signalling improves; contracting muscle also takes up glucose independently of insulin through GLUT4. Because the two components act through complementary mechanisms, the combined effect is larger than metformin alone, and by relieving the demand on beta cells it slows the progression that causes Group 1 to drift upward again.

A limitation of mean HbA1c is that a mean conceals the distribution. It does not show what proportion of each group actually reached their individual target, nor how many patients discontinued, and a mean can be produced by a small number of very large responses among people who could sustain the program while others did not respond at all. Accept also: it gives no information on side effects, cost, access, hypoglycaemia or complication rates.

Marking notes. 1 mark for correctly describing Group 1's trend with quoted values. 1 mark for correctly describing Group 2's trend with quoted values. 1 mark for an explicit comparative statement about effectiveness and durability. 2 marks for the biological explanation: 1 for identifying metformin's action, 1 for identifying that lifestyle change acts additionally on insulin resistance so the mechanisms are complementary. 1 mark for linking the divergence after month 12 to sustained action on the mechanism or to disease progression. 1 mark for a valid limitation of mean HbA1c.

Sample response outline. Mechanism. Type 2 diabetes begins with insulin resistance: muscle, liver and fat cells respond poorly to insulin, so beta cells compensate by secreting more. Over years this compensation fails (beta-cell exhaustion) and blood glucose remains persistently high. Chronic hyperglycaemia progressively damages blood vessels and nerves, producing cardiovascular disease, kidney disease, retinal damage and peripheral neuropathy. Management therefore has two simultaneous jobs: return glucose toward its range and reduce long-term complication risk.

Management matched to mechanism. Lifestyle management (activity, nutrition, sleep, weight management) acts on insulin resistance itself, reducing visceral fat and the inflammatory signalling that disrupts insulin receptor function; exercise also drives insulin-independent GLUT4 glucose uptake. Metformin, the usual first medicine, reduces hepatic glucose output and improves tissue insulin sensitivity, lowering glucose without forcing strained beta cells to secrete more. Complication risk is managed alongside glucose through blood pressure, lipid and kidney monitoring, with ACE inhibitors lowering both blood pressure and glomerular capillary pressure, and statins slowing atherosclerosis by inhibiting HMG-CoA reductase.

Monitoring and escalation. HbA1c estimates average glucose over two to three months and is evidence, not treatment. A trend that fails to reach or holds above the individual target prompts review of adherence, access and biological response, and then escalation by adding another medicine or insulin.

Future direction, evaluated. Any one of: GLP-1 receptor agonists such as semaglutide, which stimulate insulin secretion only when glucose is high, suppress glucagon, slow gastric emptying and reduce appetite, producing 15 to 17% weight loss plus cardiovascular benefit; drugs that protect beta-cell function; precision treatment matched to an individual risk profile; improved continuous glucose monitoring. A strong evaluation weighs effectiveness against safety, cost, subsidy status and access, and notes that trial efficacy commonly shrinks to lower real-world effectiveness because adherence, cost and health literacy intervene. A defensible judgement is that GLP-1 agonists are the most promising near-term direction because they act on weight, the central driver of insulin resistance, but that their population benefit depends on cost and subsidised access rather than on the biology alone.

Marking notes. 2 marks mechanism (insulin resistance, beta-cell exhaustion, chronic hyperglycaemia, complications). 2 marks management explicitly matched to that mechanism, at least two approaches with their actions named. 1 mark monitoring correctly distinguished from treatment. 1 mark escalation criteria. 2 marks evaluation of a named future direction using at least two different criteria (effectiveness, safety, cost, access, evidence quality) and reaching an explicit judgement.

Band guidance. Band 6 sustains a mechanism-to-management-to-evidence argument throughout and qualifies its judgement. Band 5 covers all elements but treats the evaluation as a list of advantages and disadvantages. Band 4 lists therapies without linking them to the mechanism, or names a future direction without evaluating it.